- Home
- WES vs NBIX Comparison
WES vs NBIX Comparison
Compare WES & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WES | NBIX |
|---|---|---|
| Founded | 2007 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3B | 15.5B |
| IPO Year | 2012 | 1996 |
Fundamental Metrics
Financial Performance| Metric | WES | NBIX |
|---|---|---|
| Price | $42.45 | $166.55 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 29 |
| Target Price | $49.54 | ★ $207.50 |
| AVG Volume (30 Days) | ★ 1.3M | 1.3M |
| Earning Date | 11-04-2026 | 11-02-2026 |
| Dividend Yield | ★ 8.48% | N/A |
| EPS Growth | N/A | ★ 41.95 |
| EPS | N/A | ★ 5.26 |
| Revenue | ★ $3,843,403,000.00 | $161,626,000.00 |
| Revenue This Year | $23.68 | $36.46 |
| Revenue Next Year | $3.77 | $17.43 |
| P/E Ratio | ★ $14.73 | $31.49 |
| Revenue Growth | 6.61 | ★ 977.51 |
| 52 Week Low | $37.75 | $122.14 |
| 52 Week High | $50.07 | $186.12 |
Technical Indicators
Market Signals| Indicator | WES | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 39.70 | 76.47 |
| Support Level | $43.86 | $152.67 |
| Resistance Level | $45.08 | $169.57 |
| Average True Range (ATR) | 0.73 | 3.61 |
| MACD | 0.05 | 2.23 |
| Stochastic Oscillator | 10.81 | 86.44 |
Price Performance
Historical ComparisonAbout WES Western Midstream Partners LP
Western Midstream Partners LP is a USA-based company which own, operate, acquire and develop midstream energy assets. The company through its subsidiary is engaged in the business of gathering, processing, compressing, treating and transporting natural gas, condensate, NGLs and crude oil. It owns or has investments in assets located in the Rocky Mountains (Colorado, Utah, and Wyoming), the Mid-Continent (Kansas and Oklahoma) and Texas.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.